Patents Assigned to Pfizer
  • Patent number: 6147214
    Abstract: An improved process, and intermediates, for the preparation of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (1,2,3,4-tetrahydro-isoquinoline-6-yl) amide (I), are disclosed. Compound (I) is useful as an inhibitor of microsomal triglyceride transfer protein and/or apolipoprotein B secretion, and which are accordingly useful for the preparation and treatment of atherosclerosis and its clinical sequelae, for lowering serum lipids, and related diseases.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: November 14, 2000
    Assignee: Pfizer Inc
    Inventor: John Anthony Ragan
  • Patent number: 6147061
    Abstract: A compound of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, synergy with cytotoxic anticancer agents, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, in combination with standard NSAID'S and analgesics and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinim, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.
    Type: Grant
    Filed: July 14, 1997
    Date of Patent: November 14, 2000
    Assignee: Pfizer Inc.
    Inventor: Lawrence A. Reiter
  • Patent number: 6147074
    Abstract: A compound of the formula ##STR1## wherein n, X, R.sup.3, R.sup.4 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: November 14, 2000
    Assignee: Pfizer Inc
    Inventors: Ralph P. Robinson, James P. Rizzi
  • Patent number: 6147090
    Abstract: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: November 14, 2000
    Assignee: Pfizer Inc.
    Inventors: Michael P. DeNinno, Christian J. Mularski, Roger B. Ruggeri, Ronald T. Wester
  • Patent number: 6143767
    Abstract: This invention provides a compound of the formula: ##STR1## and its pharmaceutically acceptable salts, wherein Ar.sup.1 is selected from the group having the formulae: ##STR2## wherein, R.sup.1 and R.sup.2 are independently hydrogen or C.sub.1 -C.sub.6 alkyl;W is (CH.sub.2).sub.a wherein n is from 1 to 3, or --CH.dbd.CH--;X is C.sub.1 -C.sub.6 alkoxy or halo C.sub.1 -C.sub.6 alkoxy; andAr.sup.2 is phenyl optionally substituted by halogen atom.These compounds are useful in the treatment of a gastrointestinal disorder, a central nervous system (CNS) disorder, an inflammatory disease, emesis, urinary incontinence, pain, migraine, sunburn, angiogenesis, diseases, disorders and adverse conditions caused by Helicobacter pylori, or the like in a mammalian subject, especially humans.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: November 7, 2000
    Assignee: Pfizer Inc
    Inventors: Hiroki Koike, Hiroaki Wakabayashi
  • Patent number: 6140343
    Abstract: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: October 31, 2000
    Assignee: Pfizer
    Inventors: Michael P. DeNinno, George T. Magnus-Aryitey, Roger B. Ruggeri, Ronald T. Wester
  • Patent number: 6140342
    Abstract: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: October 31, 2000
    Assignee: Pfizer Inc.
    Inventors: Steven W. Goldstein, Michael R. Makowski, Roger B. Ruggeri, Ronald T. Wester
  • Patent number: 6136843
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: October 24, 2000
    Assignee: Pfizer Inc
    Inventors: David James Rawson, Kevin Neil Dack, Roger Peter Dickinson, Kim James
  • Patent number: 6136861
    Abstract: The present invention relates to compounds of the formula I, as defined in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurological and psychiatric disorders.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: October 24, 2000
    Assignee: Pfizer Inc
    Inventor: Bertrand Leo Chenard
  • Patent number: 6136812
    Abstract: The invention relates to a method of treating dyskinesias associated with dopamine agonist therapy in a mammal which comprises administering to said mammal a compound, as defined herein, which is an antagonist of the AMPA receptor. Dopamine agonist therapy, as referred to in the present invention, is generally used in the treatment of a central nervous system disorder such as Parkinson's disease.
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: October 24, 2000
    Assignee: Pfizer Inc
    Inventors: Bertrand L. Chenard, Willard M. Welch, Frank S. Menniti
  • Patent number: 6131226
    Abstract: A compound of formula (I) and its pharmaceutically acceptable salts, wherein A.sup.1 and A.sup.2 are each halo; X is direct bond, CH.sub.2, CO, O, S, S(O) or S(O).sub.2 ; R.sup.1 is selected from a variety of groups such as hydrogen; substituted or unsubstituted C.sub.1-4 alkyl; substituted or unsubstituted piperidinyl; substituted or unsubstituted C.sub.5-14 cycloalkyl, bicycloalkyl or tricycloalkyl; substituted or unsubstituted C.sub.7-14 azacyclo-, azabicyclo- or azatricyclo-alkyl; bicyclo C.sub.7-10 alkenyl; benzocyclo C.sub.5-7 alkyl; and heterocyclic; R.sup.2 is hydrogen, C.sub.1-4 alkyl, substituted or unsubstituted phenyl or heterocyclic; and R.sup.3 and R.sup.4 are each C.sub.1-5 alkyl.
    Type: Grant
    Filed: February 1, 1999
    Date of Patent: October 17, 2000
    Assignee: Pfizer Inc.
    Inventor: Takafumi Ikeda
  • Patent number: 6132774
    Abstract: This invention is directed to pharmaceutical combination compositions and methods comprising (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydr onaphthalene-2-ol or a pharmaceutically acceptable salt thereof and parathyroid hormone or a biologically active fragment thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass and frailty.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: October 17, 2000
    Assignee: Pfizer Inc.
    Inventors: HuaZhu Ke, David D. Thompson
  • Patent number: D432641
    Type: Grant
    Filed: April 7, 1998
    Date of Patent: October 24, 2000
    Assignee: Pfizer Inc.
    Inventor: Robert Burrows
  • Patent number: D432714
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: October 24, 2000
    Assignee: Pfizer Inc.
    Inventors: Stuart M. Leslie, Charles Curtiss, Chen Jiang
  • Patent number: D433121
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: October 31, 2000
    Assignee: Pfizer Inc
    Inventor: Robert Burrows
  • Patent number: D433122
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: October 31, 2000
    Assignee: Pfizer Inc.
    Inventor: Robert Burrows
  • Patent number: D433499
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: November 7, 2000
    Assignee: Pfizer Inc
    Inventor: Robert Burrows
  • Patent number: D433500
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: November 7, 2000
    Assignee: Pfizer Inc
    Inventor: Robert Burrows
  • Patent number: D433501
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: November 7, 2000
    Assignee: Pfizer Inc
    Inventor: Robert Burrows
  • Patent number: D433750
    Type: Grant
    Filed: April 7, 1998
    Date of Patent: November 14, 2000
    Assignee: Pfizer Inc
    Inventor: Robert Burrows